SCHEMBL2440970

SCHEMBL2440970

Cc1ccc2onc(NC(=O)c3ccc(F)cc3F)c2c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
HTR1F P30939 1/20 0.51
TP53 P04637 4/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
CTNNB1 P35222 1/20 0.46
TCF7L2 Q9NQB0 1/20 0.46
LMNA P02545 3/20 0.45
ALDH1A1 P00352 2/20 0.45
SNCA P37840 1/20 0.43
NPC1 O15118 4/20 0.42
RAB9A P51151 4/20 0.42
RXFP1 Q9HBX9 1/20 0.42
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPK1 P28482 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2439738 0.91 TP53 (0.53) MAPTTDP1HTR1FTP53SMN1; SMN2
SCHEMBL2439567 0.87 SMN1; SMN2 (0.56) MAPTTDP1TP53SMN1; SMN2CTNNB1
SCHEMBL2437675 0.86 HTR1F (0.48) MAPTTDP1HTR1FTP53SMN1; SMN2
SCHEMBL2440202 0.84 SMN1; SMN2 (0.68) MAPTTDP1HTR1FTP53SMN1; SMN2
SCHEMBL2439676 0.82 TP53 (0.54) MAPTTDP1TP53SMN1; SMN2LMNA
SCHEMBL2441233 0.81 SMN1; SMN2 (0.74) MAPTTDP1TP53SMN1; SMN2LMNA
SCHEMBL2440321 0.80 SMN1; SMN2 (0.55) MAPTTP53SMN1; SMN2LMNAALDH1A1
SCHEMBL2438553 0.79 RAB9A (0.54) MAPTTP53SMN1; SMN2LMNANPC1
SCHEMBL2437296 0.77 SMN1; SMN2 (0.61) MAPTTP53SMN1; SMN2LMNAALDH1A1
SCHEMBL2437260 0.77 KCNK3 (0.50) MAPTTP53SMN1; SMN2LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP claimed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US claimed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP claimed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO claimed
EP-1893589-B1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS GRUENENTHAL GMBH (DE) 2011-09-14 EP disclosed
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof GRUENENTHAL GMBH (DE) 2008-12-18 US disclosed
EP-1893589-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2008-03-05 EP disclosed
WO-2006131296-A1 SUBSTITUTED N-BENZO [D] ISOXAZOL-3-YL-AMINE DERIVATIVES AS INHIBITORS OF MGLUR5, SEROTONINE (5-HT) AND NORADRENALINE RECEPTORS, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS Grünenthal GmbH (DE) 2006-12-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312301-A1 Substituted N-Benzo[D]Isoxazol-3-Yl-Amine Compounds as Inhibitors of Mglur5, Serotonin (5-Ht) and Noradrenaline Receptors, and Uses Thereof HTR5A, NPY5R, GRM5 MAPT 1615/4885TDP1 3169/4885HTR1F 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.